EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)

Scott Demarest, Shafali Jeste, Nitin Agarwal, Dimitrios Arkilo, Mahnaz Asgharnejad, Samuel Hsiao, Ronald Thibert

Epilepsy & Behavior · 2023

DOI: 10.1016/j.yebeh.2023.109173 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Epilepsy & Behavior, 2023. Verfasst von Scott Demarest und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Neurology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA. Electronic ad…. Hauptthemen laut MEDLINE: Spasms, Infantile, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A., Takeda Pharmaceutical Company Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Chromosome 15q duplication (Dup15q) syndrome and cyclin‑dependent kinase-like 5 deficiency disorder (CDD) are rare neurodevelopmental disorders associated with epileptic encephalopathies, with a lack of specifically approved treatment options. ARCADE assessed the efficacy and safety of adjunctive soticlestat (TAK-935) for the treatment of seizures in patients with Dup15q syndrome or CDD (NCT03694275). METHODS: ARCADE was a phase II, open-label, pilot study of soticlestat (≤300 mg/day twice daily, weight-adjusted) in pediatric and adult patients 2-55 years of age with Dup15q syndrome or CDD who experienced ≥3 motor seizures per month in the 3 months before screening and at baseline. The 20-week treatment period consisted of a dose-optimization period and a 12-week maintenance period. Efficacy endpoints included the change from baseline in motor seizure frequency during the maintenance period and the proportion of treatment responders. Safety endpoints included the incidence of treatment-emergent adverse effects (TEAEs). RESULTS: The modified-intent-to-treat population included 20 participants who received ≥1 dose of soticlestat and had ≥1 efficacy assessment (Dup15q syndrome, n = 8; CDD, n = 12). Soticlestat administration during the maintenance period was associated with a median change from baseline in motor seizure frequency of +11.7% in the Dup15q syndrome group and -23.6% in the CDD group. Reductions in all seizure frequency of -23.4% and -30.5% were also observed during the maintenance period in the Dup15q syndrome group and the CDD group, respectively. Most TEAEs were of mild or moderate severity. Serious TEAEs were reported by three patients (15.0%); none were considered drug related. The most common TEAEs were constipation, rash, and seizure. No deaths were reported. CONCLUSIONS: Adjunctive soticlestat treatment was associated with a decrease in motor seizure frequency from baseline in patients with CDD and a decrease in all seizure frequency in both patient groups. Soticlestat treatment was associated with an increase in motor seizure frequency in patients with Dup15q syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spasms, InfantileDrug-Related Side Effects and Adverse ReactionsProtein Serine-Threonine KinasesPilot ProjectsHumansAnticonvulsantsDouble-Blind MethodTreatment OutcomeAdultDrug Therapy, CombinationSeizuresInfantChildPiperidinesPyridinesEpileptic Syndromes

Stichwörter der Autor:innen

24S-hydroxycholesterolCDKL5 deficiency disorderCholesterol 24-hydroxylaseDevelopmental and epileptic encephalopathiesDup15q syndromeSoticlestat

Substanzen

Protein Serine-Threonine KinasesAnticonvulsantssoticlestatPiperidinesPyridinesCDKL5 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics and Neurology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA. Electronic address: Scott.Demarest@childrenscolorado.org.
  • Division of Neurology, Children's Hospital Los Angeles, Los Angeles, California, USA. Electronic address: sjeste@chla.usc.edu.
  • Division of Pediatric Epilepsy, Minnesota Epilepsy Group, P.A., and Children's Minnesota, St Paul, Minnesota, USA. Electronic address: NAgarwal@mnepilepsy.net.
  • Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA. Electronic address: arkdimi@hotmail.com.
  • Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA. Electronic address: mahnaz.asgharnejad@takeda.com.
  • Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA. Electronic address: sam.hsiao@takeda.com.

Förderung

  • Takeda Pharmaceuticals U.S.A.
  • Takeda Pharmaceutical Company Limited

Zitieren

APA

Demarest, S., Jeste, S., Agarwal, N., Arkilo, D., Asgharnejad, M., Hsiao, S., & Thibert, R. (2023). Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE). Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2023.109173

Vancouver

Demarest S, Jeste S, Agarwal N, Arkilo D, Asgharnejad M, Hsiao S, et al. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE). Epilepsy & Behavior. 2023. doi:10.1016/j.yebeh.2023.109173

BibTeX
@article{Demarest2023,
  author = {Demarest, Scott and Jeste, Shafali and Agarwal, Nitin and Arkilo, Dimitrios and Asgharnejad, Mahnaz and Hsiao, Samuel and Thibert, Ronald},
  title = {Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)},
  journal = {Epilepsy & Behavior},
  year = {2023},
  doi = {10.1016/j.yebeh.2023.109173}
}
Kostenlos starten →